Here, we show that the integrin-activating compound 7HP349, a structural analogue of THI0019 currently in clinical development (ClinicalTrials.gov NCT04508179), increases tumor-specific T cell activation and localization to a non–T cell–inflamed cold TME typically characterized by low ICAM-1 expression and enhances the antitumor activity of CTLA-4 and PD-1/L1 ICB therapies. Here, CTLA4 is linked to neoplasm.